key: cord-0887949-f2jx56fi authors: Bridge, J.; Meng, Y.; Zhu, W.; Fitzmaurice, T.; McCann, C.; Addison, C.; Wang, M.; Merritt, C.; Franks, S.; Mackey, M.; Messenger, S.; Sun, R.; Zhao, Y.; Zheng, Y. title: Development and External Validation of a Mixed-Effects Deep Learning Model to Diagnose COVID-19 from CT Imaging date: 2022-01-30 journal: nan DOI: 10.1101/2022.01.28.22270005 sha: bd011e69ddf594e66bee729a9e63173f020ba79d doc_id: 887949 cord_uid: f2jx56fi Objectives To develop and externally geographically validate a mixed-effects deep learning model to diagnose COVID-19 from computed tomography (CT) imaging following best practice guidelines and assess the strengths and weaknesses of deep learning COVID-19 diagnosis. Design Model development and external validation with retrospectively collected data from two countries. Setting Hospitals in Moscow, Russia, collected between March 1, 2020, and April 25, 2020. The China Consortium of Chest CT Image Investigation (CC-CCII) collected between January 25, 2020, and March 27, 2020. Participants 1,110 and 796 patients with either COVID-19 or healthy CT volumes from Moscow, Russia, and China, respectively. Main outcome measures We developed a deep learning model with a novel mixed-effects layer to model the relationship between slices in CT imaging. The model was trained on a dataset from hospitals in Moscow, Russia, and externally geographically validated on a dataset from a consortium of Chinese hospitals. Model performance was evaluated in discriminative performance using the area under the receiver operating characteristic (AUROC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). In addition, calibration performance was assessed using calibration curves, and clinical benefit was assessed using decision curve analysis. Finally, the model's decisions were assessed visually using saliency maps. Results External validation on the large Chinese dataset showed excellent performance with an AUROC of 0.956 (95% CI: 0.943, 0.970), with a sensitivity and specificity, PPV, and NPV of 0.879 (0.852, 0.906), 0.942 (0.913, 0.972), 0.988 (0.975, 1.00), and 0.732 (0.650, 0.814). Conclusions Deep learning can reduce stress on healthcare systems by automatically screening CT imaging for COVID-19. However, deep learning models must be robustly assessed using various performance measures and externally validated in each setting. In addition, best practice guidelines for developing and reporting predictive models are vital for the safe adoption of such models. The authors do not own any of the patient data, and ethics approval was not needed. The lead 2 author affirms that this manuscript is an honest, accurate, and transparent account of the study 3 being reported, that no important aspects of the study have been omitted, and that any 4 discrepancies from the study as planned (and, if relevant, registered) have been explained. Patients 5 and the public were not involved in the study. 6 Funding 7 This study was funded by EPSRC studentship (No. 2110275), EPSRC Impact Acceleration Account 8 (IAA) funding, and Amazon Web Services. 9 Summary 10 What is already known on this topic 11 • Deep learning can diagnose diseases from imaging data automatically 12 • Many studies using deep learning are of poor quality and fail to follow current best practice 13 guidelines for the development and reporting of predictive models 14 • Current methods do not adequately model the relationship between slices in CT volumetric 15 data 16 What this study adds 17 • A novel method to analyse volumetric imaging data composed of slices such as CT images 18 using deep learning 19 • Model developed following current best-practice guidelines for the development and 20 reporting of prediction models 21 22 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Introduction 1 Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by severe acute 2 respiratory syndrome coronavirus 2 (SARS-CoV-2). Virus clinical presentation ranges from mild cold-3 like symptoms to severe viral pneumonia, which can be fatal 1 . While some countries have achieved 4 relative control through lockdowns, future outbreaks and new strains are expected to continue, with 5 many experts believing the virus is here to stay 2 . Detection and isolation is the most effective way to 6 prevent further spread of the virus. Even with effective vaccines becoming widely available, with the 7 threat of continued waves and new potentially vaccine-resistant variants, it is vital to further 8 develop diagnostic tools for COVID-19. These tools will likely also apply to future outbreaks of other 9 similar diseases as well as common diseases such as pneumonia. 10 The diagnosis of COVID-19 is usually determined by Reverse Transcription Polymerase Chain 11 Reaction (RT-PCR), but this is far from being a gold standard. A negative test does not necessarily 12 indicate a negative diagnosis, with one recent review finding that RT-PCR has a real-world sensitivity 13 of around 70% and a specificity of 95% 3 . Furthermore, an individual patient data systematic review 4 14 found that RT-PCR often fails to detect COVID-19, and early sampling is key to reducing false 15 negatives. Therefore, these tests are often more helpful to rule in COVID-19 rather than ruling out. 16 If a patient presents with symptoms of COVID-19, but an RT-PCR test is negative, then further tests 17 are often required 1 . Consecutive negative tests with at least a one-day gap are recommended; 18 however, this still does not guarantee that the patient is negative for COVID-19 5 . Computed 19 tomography (CT) can play a significant role in diagnosing COVID-19 6 . Given the excessive number of 20 COVID-19 cases worldwide and the strain on resources expected, automated diagnosis might reduce 21 the burden on reporting radiologists. 22 CT images are made up of many slices, creating a three dimensional (3D)-like structure. Previous 23 approaches, such as those used by Li et al. 7 and Bai et al. 8 , treat the image as separate slices and use 24 a pooling layer to concatenate the slices. An alternative approach assumes the slices form a 3D 25 structure and use a 3D CNN, such as that proposed in CoviNet 9 . A fundamental limitation of these 26 methods is the need for the same number of slices as their inputs, but the number of slices often 27 varies between different CT volumes. Instead, we propose using a novel mixed-effects layer to 28 consider the relationship between slices in each scan. Mixed-effects models are commonly used in 29 traditional statistics 10 11 , but we believe this is the first time that mixed-effects models have been 30 utilised in such a way. It has been observed that some lobes of the lung are more often affected by 31 COVID-19 than others 12 13 with lower lobe distribution being a prominent feature of COVID-19 14 , the 32 fixed-effects take this into account by considering where each slice is located within the scan. 33 Deep learning has shown great potential in the automatic classification of disease, often achieving 34 expert-level performance. Such models could screen and monitor COVID-19 by automatically 35 analysing routinely collected CT images. As observed by Wynants et al. 15 and Roberts et al. 16 , many 36 models are already developed to diagnose COVID-19, which often obtain excellent discriminative 37 performance; however, very few of these models, if any, are suitable for clinical use, mainly due to a 38 lack of robust analysis and reporting. These models often suffer from common pitfalls, making them 39 unsuitable for broader adoption. Roberts et al. 16 identified three common areas in which models 40 often fail these are: (1) a lack of adequately documented methods for reproducibility, (2) failure to 41 follow established guidelines and best practices for the development of deep learning models, and 42 (3) an absence of external validation displaying the model's applicability to a broader range of data 43 outside of the study sample. Failure to address these pitfalls leads to profoundly flawed and biased 44 models, making them unsuitable for deployment. 45 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22270005 doi: medRxiv preprint In this work, we aim to address the problems associated with previous models by following 1 guidelines for the reporting 17 18 and development 19 of prediction models to ensure that we have 2 rigorous documentation allowing the methods developed here to be replicated. In addition, we will 3 make code and the trained model publicly available at [github.com/JTBridge/ME-COVID19] to 4 promote reproducible research and facilitate adoption. Finally, we use a second dataset from a 5 country other than the development dataset to externally validate the model and report a range of 6 performance measures evaluating the model's discrimination, calibration, and clinical usefulness. 7 Hence, our main aim is to develop a mixed-effects deep learning model to accurately classify images 8 as healthy or COVID-19, following best practice guidelines. Our secondary aim is to show how deep 9 learning predictive algorithms can satisfy current best practice guidelines to create reproducible and 10 less biased models. 11 Our proposed method consists of a feature extractor and a two-stage generalised linear mixed-13 effects model (GLMM) 20 , with all parameters estimated within the deep learning framework using 14 backpropagation. First, a series of CT slices forming a CT volume is input to the model. In our work, 15 we use 20 slices. Next, a convolutional neural network (CNN) extract relevant features from the 16 model and creates a feature vector for each CT slice. Then, a mixed-effects layer concatenates the 17 feature vectors into a single vector. Finally, a fully connected layer followed by a sigmoid activation 18 gives a probability of COVID-19 for the whole volume. The mixed effects and fully connected layer 19 with sigmoid activation are analogous to a linear GLMM in traditional statistics. The overall 20 framework is shown in Figure 1 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22270005 doi: medRxiv preprint Feature extractor 1 For the feature extractor, we use a CNN. In this work, we chose InceptionV3 21 as it is relatively 2 efficient and commonly used. InceptionV3 outputs a feature vector of length 2048. To reduce the 3 time needed to reach convergence, we pretrained the CNN on ImageNet 22 . A CNN is used for each 4 slice, with shared weights between CNNs; this reduces the amount of computational power 5 required. Following the CNN, we used a global average pooling layer to reduce each image to a 6 feature vector for each slice. We then added a dropout of 0.6 to improve generalizability to unseen 7 images. We form the feature vectors into a matrix of shape 20 × 2048. Although we used 8 InceptionV3 21 here, other networks would also work and may provide better performance on other 9 similar tasks. We then need to concatenate these feature vectors into a single feature vector for the 10 whole volume; normally, pooling is used, in our work we propose using a mixed-effects models. 11 Mixed-effects network 12 We propose utilising a novel mixed-effects layer to model the relationship between slices. Mixed-13 effects models are a statistical model consisting of a fixed-effects part and a random-effects part. 14 The fixed-effects part models the relationship within the CT slice; the random effects can model the 15 spatial correlation between CT slices within the same image 11 . For volumetric data, the number of 16 slices may differ significantly due to various factors such as imaging protocol and the size of the 17 patient. Some volumes may have fewer images than the model is designed to use, which leads to 18 missing data. Mixed-effects models can deal with missing data provided the data are missing at 19 random. The mixed-effects model is given by 20 where , , , are vectors of outcomes, fixed effects design matrix of shape 20 × 2048, 22 random effects design matrix of shape 20 × 20, and vector of error unknown random errors of the 23 ith patient of shape 20, respectively, and , are fixed and random effects parameters, both of 24 length 20. We assume that the random effects are normally distributed with 0 and variance 25 We also assume independence between the random effects and the error term. 27 The fixed effects design matrix, , is made up of the feature vectors output from the feature 28 extraction network. For the random effects design matrix, , we use an identity matrix with the 29 same size as the number of slices; in our experiments, this is 20. The design matrix is then given by 30 This matrix easily generalises to any number of slices. If the distance between slices is not uniform, 32 the values can be altered accordingly. We assumed no particular correlation matrix. We included the 33 fixed and random intercept in the model. All parameters for the mixed-effects layer were initialised 34 using the Gaussian distribution with mean 0 and standard deviation 0.05. 35 A type of mixed-effects modelling has previously been combined with deep learning for gaze 36 estimation 23 . However, their mixed-effects method is very different from our proposed method; 37 they used the same design matrix for fixed and random effects. In addition, they also estimated 38 random-effects parameters with an expectation-maximisation algorithm, which was separate from 39 the fixed effects estimation, which used deep learning. In our work, we utilise a spatial design matrix 40 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22270005 doi: medRxiv preprint to model the spatial relationship between slices and estimate parameters within the deep learning 1 framework using backpropagation without the need for multiple stages. 2 3 As the parameters in the model are all estimated using backpropagation, we must ensure that the 4 assumption of normally distributed random effects parameters with mean zero is valid. We achieve 5 this by introducing a loss function for the random effects parameters, which enforces a mean, 6 skewness, and excess kurtosis of 0. We measure skewness using the adjusted Fisher-Pearson 7 standardised moment coefficient 8 3/2 9 and the excess kurtosis using 10 where is the length of , ̅ is the mean of and [⋅] is the expectation function. The Gaussian 12 distribution has a kurtosis of 3; therefore, the excess kurtosis is given by the kurtosis minus 3. This 13 formula for this fixed-effects parameters loss function which we aim to minimise is then given by 14 For the classification, we use the Brier Score 24 as the loss function, which is given by 16 where is the total number of samples, is the predicted probability of sample and is the 18 observed outcome of sample . The Brier score is the same as the mean squared error of the 19 predicted probability. 20 We chose to use the Brier Score over the more commonly used binary cross-entropy because it can 21 be decomposed into two components: refinement and calibration. Calibration is often overlooked in 22 deep learning models but is vital to assess the safety of any prediction model. The refinement 23 component combines the model's resolution and uncertainty and measures the model's 24 discrimination. The calibration component can be used as a measure of the model calibration. 25 Therefore the Brier Score can be used to optimize both the discrimination and calibration of the 26 model. The overall loss function is given by 27 A scaling factor could be introduced to weight one part of the loss function as more important than 29 the other; however, we give both parts of the loss function equal weighting in our work. 30 We also transformed the labels as suggested by Platt 25 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22270005 doi: medRxiv preprint and 1 + = + + 1 + + 2 2 respectively, where − and + are the total number of negative and positive cases in the training 3 set. This is similar to label smoothing as commonly used in deep learning, but the new targets are 4 chosen by applying Baye's Rule to the out-of-sample data to prevent overfitting. 5 Classification layer 6 The output of the mixed-effects layer is a single vector, which is the same length as the number of 7 slices used. For example, in our work, we had a vector of length 20. Furthermore, we used a fully 8 connected layer with sigmoid activation to obtain a probability of the scan showing COVID-19; the 9 sigmoid activation is analogous to the logistic link function in traditional statistics. Finally, we added 10 an L1 regularisation term of 0. level indicating better calibration than the last 28 . The fourth and most stringent level (strong 23 calibration) requires the correct model to be known, which in turn requires predictors to be non-24 continuous, and an infinite amount of data to be used and is therefore considered utopic. We 25 consider the third level (moderate calibration) using calibration curves. Moderate calibration will 26 ensure that the model is at least not clinically harmful. Finally, measures of clinical usefulness assess 27 the clinical consequences of the decision and acknowledge that a false positive may be more or less 28 severe than a false negative. 29 Firstly, the discriminative performance is assessed using AUROC using the pROC package in R 29 , with 30 confidence intervals constructed using DeLong's 30 method. For sensitivity, specificity, positive 31 predictive value (PPV), and negative predictive value (NPV), we use the ReportROC 31 package in R 29 ; 32 with 95% confidence intervals constructed using the simple asymptotic formula. Secondly, we assess 33 model calibration using calibration curves created using the CalibrationCurves package 28 , which is 34 based on the rms 32 package. Finally, we assess the clinical usefulness of the model using decision 35 curve analysis 33 . Net benefits are given at various thresholds, and models which reach zero net 36 benefit at higher thresholds are considered more clinically useful. Two brief sensitivity analyses are 37 performed, one assessing the model's ability to deal with missing data and the other assessing its 38 ability to deal with noise. To improve the model's interpretability and reduce the black-box nature, 39 we produce saliency maps 34 that show which areas of the image are helpful to the model in the 40 prediction. We also check the assumption of normally distributed random-effects parameters. 41 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22270005 doi: medRxiv preprint Comparison models 1 To assess the added benefit of using our mixed-effects method, we compare against networks that 2 use alternative methods. Both COVNet 7 and a method proposed by Bai to extract features followed by a series of full-connected layers with batch normalisation and 7 dropout; average pooling is then used to concatenate the feature vectors before classification. While 8 max pooling is simple and computationally efficient, it cannot deal with pose variance and does not 9 model the relationship between slices. 10 An alternative method to pooling is treating the scans as 3D, such as in CoviNet 37 . CoviNet takes the 11 whole scan and uses a 16 layer 3D CNN followed by pooling and fully connected layers. We 12 implemented these models as described in their respective papers. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22270005 doi: medRxiv preprint either healthy or COVID-19 infected lungs. The scans were performed in Moscow hospitals between 1 March 1, 2020, and April 25, 2020. We split the dataset into two sets for training and internal 2 validation on the patient level. The training set is used to train the model, and the internal validation 3 set is used to select the best model based on the loss at each epoch; this helps prevent overfitting on 4 the training set. In addition, we obtained images from a publicly available dataset published by 5 Zhang et al. 45 consisting of CT images from a consortium of Chinese hospitals. 6 Overall, this allows us to perform external geographical validation in another country and to better 7 evaluate the developed model. In addition, we will be able to assess how well a deep learning model 8 generalises to other populations. A summary of all the datasets used is shown in Table 1 . We have 9 923 patients in the training set and at least 200 patients in each class for the external validation set. 10 Data pre-processing and augmentation 20 The MosMed dataset was converted from Dicom image format into PNG, normalised to have a mean 21 of 120 and a variance of 95. Images were ordered from the top of the lungs to the bottom. During 22 training, we applied random online data augmentation to the images. This alters the image slightly 23 and gives the effect of increasing the training dataset size, although this is not as good as expanding 24 the training dataset with more samples. First, we adjusted the brightness and contrast between 70% 25 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. and 130%. We then rotated the image plus or minus 45 degrees and cropped the image up to 20% 1 on each side. Finally, we flipped the image horizontally and vertically with a probability of 50% each. 2 All random values were chosen using the uniform distribution except for the flips, which were 3 chosen using a random bit. 4 The dataset taken from Zhang et al. 45 required a large amount of sorting to be made suitable for use. 5 Some of the scans were pre-segmented and only showed the lung areas, while others showed the 6 whole CT scan. We removed any pre-segmented images. Identifying information on some images 7 had to be cropped to reduce bias in the algorithm. In addition, many of the scans were duplicates 8 but were not labelled as such, and many scans were incomplete, only showing a few lung slices or 9 not showing any lung tissue at all. We only used complete scans with one scan per patient. Finally, 10 some scans needed to be ordered top to bottom. Using the bilinear sampling algorithm, all images 11 were resized to 256 by 256 pixels, and image values were divided by 255 to normalise between 0 12 and 1. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Calibration curves in Figure 5 show reasonable calibration for the mixed-effects model, although 5 recalibration may improve performance. The other models do not have good calibration and likely 6 provide harmful predictions. The decision curve in Figure 6 shows that the model is of great clinical 7 benefit compared to the treat all and treat none approach. 8 It is vital to remember that the model was selected using this internal testing set to avoid overfitting 9 on the training set; therefore, these results are biased, and the external validation results are more 10 representative of the true model performance. 11 Table 3 . 28 Similar to the internal validation, Figure 7 shows reasonable calibration for the mixed-effects model, 29 although some recalibration may improve performance. Again, the comparison models could give 30 harmful predictions as they are poorly calibrated. The decision curve in Figure 8 shows that the 31 model is of great clinical benefit compared to the treat all and treat none approach. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22270005 doi: medRxiv preprint need for robust external validation in each intended setting. Nevertheless, the results show that the 1 proposed method better generalises to external geographical datasets and provides less harmful 2 predictions when compared to the four previously proposed methods. 3 4 Table 3 : Area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, 5 positive predictive value (PPV) and negative predictive value (NPV) on the external validation 6 dataset. Point estimates and 95% confidence intervals were calculated using De Long's method for 7 AUROC and 2000 sample bootstrapping for sensitivity, specificity, PPV, and NPV. 8 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. It is vital to understand how the algorithm makes decisions and to check that it identifies the correct 9 features within the image. Saliency maps can be used as a visual check to see what features the 10 algorithm is learning. For example, the saliency maps in Figure 9 show that the model correctly 11 identifies the diseased areas of the scans. We used 100 samples with a smoothing noise of 0.05 to 12 create these saliency maps. 13 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. Mixed-effects models are capable of accounting for missing data. However, only one image had less 11 than 20 slices; hence, we could not adequately assess if our model can indeed maintain good 12 performance with missing data. Here, we rerun the analysis using the same dataset, using the same 13 model and weights; however, we reduce the number of slices available as testing data inputs to 14 simulate missing data. Blank images replace these slices. We uniformly sampled the slices choosing 15 between 10 and 19 slices; this equates to between 5 and 50% missing data for the model. We ran 16 inference at each level of missingness and briefly show the AUROC to determine at which point the 17 predictive performance is significantly reduced. 18 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; The plot of AUROCs at different levels of missingness is shown in Figure 10 , along with 95% 1 confidence intervals. We can see that at 20% missingness, there is a statistically significant decrease 2 in predictive performance. Although, even at 50% missingness, the model still performs relatively 3 well, with an AUROC of 0.890 (95% CI: 0.868, 0.912). It should be noted that this does not mean that 4 there is no reduction in performance at 5-15% missingness, only that the reduction was not 5 statistically significant at the 95% confidence level. 6 7 Figure 10 : AUROC values at different levels of missingness. At 20% missingness, the loss in 8 performance becomes statistically significant; however, even with 50% missing images, the model 9 still has a reasonably high AUROC. 10 Deep learning models can be susceptible to adversarial attacks 46 , where minor artefacts or noise on 11 an image can cause the image to be misclassified, even when the image does not look significantly 12 different to a human observer. Here, we perform a brief sensitivity analysis by adding a small 13 Gaussian noise to the image. We tested the model performance on the external dataset, with each 14 image having a random Gaussian noise added. Experiments were conducted with standard 15 deviations of 0 up to 0.005 in increments of 0.001 added to the normalised image. We did not add 16 Gaussian noise in the data augmentation so that the model is not explicitly trained to deal with this 17 kind of attack. 18 When using a variance of 0, the images are unchanged, and the results are the same as the standard 19 results above. We present results on the Zhang et al. 45 dataset. Example images for each level of 20 variance are shown in Figure 11 , and a graph showing the reduction in AUROC is shown in Figure 12 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The AUROC falls steadily with increased noise in the image. 9 Artificial intelligence is set to revolutionise healthcare, allowing large amounts of data to be 11 processed and analysed automatically, reducing pressure on stretched healthcare services. These 12 tools can aid clinicians in monitoring and managing both common conditions and outbreaks of novel 13 diseases. However, these tools must be assessed adequately, and best practice guidelines for 14 reporting and development must be followed closely to increase reproducibility and reduce bias. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Compared to previously proposed models, our model showed similar discriminative performance to 6 one existing method; however, our method generalised better to an external geographical validation 7 set and showed improved calibration performance. Interestingly, in both internal and external 8 validation, the sensitivity and NPV are similar in all models. However, the specificity and PPV are 9 statistically significantly improved for the mixed-effects model in the external validations dataset. 10 The performance of the proposed model in the external validation set is similar to that reported by 11 PCR testing 3 . However, a direct comparison should not be made as PCR testing on this exact dataset 12 is unavailable. 13 There are several limitations of the study that should be highlighted and improved in future work. 14 Firstly, we have only performed external geographical validation in a single dataset. Further external 15 validation, both geographical and temporal, is needed on many datasets to determine if the model is 16 correct in each intended setting. Although we performed a brief sensitivity analysis here, more 17 extensive work on adversarial attacks is needed. Future studies could consider following the method 18 proposed by Goodfellow maps showed that the model was not using the features of COVID-19 to make the diagnosis and was 27 instead using the area around the image. We concluded that the images for each class were slightly 28 different, perhaps due to different imaging protocols, and the algorithm was learning the image 29 format rather than the disease. We then used the MosMed dataset for training and the Zhang et 30 al. 45 dataset for external validation. This highlights the need for good quality training data and 31 external validation and visualisation. 32 Future studies should validate models and follow reporting guidelines such as TRIPOD 17 or the 33 upcoming QUADAD-AI 48 and TRIPOD-AI 49 to bring about clinically useful and deployable models. 34 Further research could look deeper into the areas of images identified by the algorithm as shown on 35 the saliency maps; this could potentially identify new features of COVID-19 which have gone 36 unnoticed. Before any model can be fully deployed, clinical trials are needed to study the full impact 37 of using such algorithms to diagnose COVID-19 and the exact situations in which such a model may 38 be used. In-clinic prospective studies comparing the performance deep learning models with RT-PCR 39 and lateral flow tests should be carried out to determine how deep learning compares; this will show 40 whether deep learning could be used as an automated alternative to RT-PCR testing. 41 This study indicates that deep learning could be suitable for screening and monitoring of COVID-19 42 in a clinical setting; however, validation in the intended setting is vital, and models should not be 43 adopted without this. It has been observed that the quality of reporting of deep learning prediction 44 models is usually very poor; however, with a bit of extra work and by following best practice 45 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22270005 doi: medRxiv preprint guidelines, this problem can be overcome. This study highlights the importance of robust analysis 1 and reporting of models with external validation. 2 3 Coronavirus disease 2019 (COVID-19) -Symptoms, diagnosis and treatment Covid-19 will become endemic but with decreased potency over time, scientists 8 believe Interpreting a covid-19 test result At what times during infection is SARS-CoV-2 detectable and 12 no longer detectable using RT-PCR-based tests? A systematic review of individual participant 13 data A case of coronavirus disease 2019 with twice negative nucleic 15 acid testing within 8 days Role of computed tomography in COVID-19 Using Artificial Intelligence to Detect COVID-19 and Community-acquired 19 Pneumonia Based on Pulmonary CT: Evaluation of the Diagnostic Accuracy Artificial Intelligence Augmentation of Radiologist Performance in 22 Distinguishing COVID-19 from Pneumonia of Other Origin at Chest CT Covid-19 diagnosis using machine learning analyses for computerized 25 tomography images Spatial statistical modelling of capillary non-perfusion 28 in the retina Spatial linear mixed effects modelling for OCT images: SLME model. 30 Chest CT scan features from 302 patients with COVID-32 19 in Jordan Lobar distribution of COVID-19 pneumonia based 35 on chest computed tomography findings; A retrospective study CT findings in a novel coronavirus disease (COVID-19) pneumonia at 38 initial presentation Prediction models for diagnosis and prognosis of 41 covid-19: systematic review and critical appraisal Common pitfalls and recommendations for using machine 44 learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans. 45 Transparent reporting of a multivariable prediction 47 model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement Checklist for artificial intelligence in medical imaging (CLAIM): A guide 1 for authors and reviewers PROBAST: A tool to assess the risk of bias and applicability 4 of prediction model studies Linear and generalized linear mixed models and their applications Rethinking the inception architecture for computer vision ImageNet: A large-scale hierarchical image database Mixed effects neural networks (MeNets) with applications to gaze 15 estimation Probabilistic outputs for support vector machines and comparisons to regularized 20 likelihood methods Assessing the performance of prediction models: A 22 framework for traditional and novel measures Calibration: the Achilles heel of predictive 24 analytics A calibration hierarchy for risk models was defined: 26 from utopia to empirical data Comparing the Areas under Two or More Correlated 30 Receiver Operating Characteristic Curves: A Nonparametric Approach reportROC: an easy way to report ROC analysis Decision curve analysis: a novel method for evaluating prediction models Removing noise by adding noise. arXiv 2017 Efficientnet: Rethinking model scaling for convolutional neural networks Covid-19 diagnosis using machine learning analyses for computerized 43 tomography images Tensorflow: A system for large-scale machine learning. 12th {USENIX} symposium on operating 47 systems design and implementation pROC: an open-source package for R and S+ to analyze and 49 compare ROC curves Elegant Graphics for Data Analysis A method for stochastic optimization Minimum sample size for developing a multivariable prediction 3 model: PART II -binary and time-to-event outcomes MosMedData: Data set of 1110 chest CT scans 6 performed during the COVID-19 epidemic Clinically applicable AI system for accurate diagnosis, quantitative 9 measurements, and prognosis of COVID-19 pneumonia using computed tomography Explaining and harnessing adversarial examples External validation of clinical prediction models: simulation-14 based sample size calculations were more reliable than rules-of-thumb A quality assessment tool for artificial intelligence-17 centered diagnostic test accuracy studies: QUADAS-AI Protocol for development of a reporting guideline 20 (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction 21 model studies based on artificial intelligence